26
|
Scala D, Rega D, Ruffolo F, Pace U, Sassaroli C, Cardone E, Grimaldi A, Caraco' C, Mozzillo N, Delrio P. Electrochemotherapy for rectal cancer after neoadjuvant radiotherapy: A case report. Eur J Surg Oncol 2015. [DOI: 10.1016/j.ejso.2014.10.037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
27
|
Sassaroli C, Scala D, Rega D, Pace U, Ruffolo F, Cassata A, Delrio P. 428. Proactive HIPEC treatment of pelvic T4 locally advanced cancer and recurrent pelvic colorectal cancer: Preliminary results. Eur J Surg Oncol 2014. [DOI: 10.1016/j.ejso.2014.08.418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
28
|
Sassaroli C, Scala D, Rega D, Ruffolo F, Pace U, Cassata A, Delrio P. 247. Pelvic resection: Indications, technical considerations and outcomes of a single center series. Eur J Surg Oncol 2014. [DOI: 10.1016/j.ejso.2014.08.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
29
|
Martines C, Cordio S, Aprile G, Galiano A, Lonardi S, Rosati G, Avallone A, Pini S, Leo S, Lutrino S, Uccello M, Delrio P, Franco S, Bordonaro R. Safety and Efficacy of Preoperative Chemoradiotherapy (Crt) in Locally Advanced Rectal Cancers (Larc): a Retrospective Italian Survey of 389 Elderly Patients. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.90] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Pace U, Rega D, Scala D, Montesarchio L, Delrio P. Skin bridge loop ileostomy: technical details. Tech Coloproctol 2014; 18:855-6. [PMID: 24718776 DOI: 10.1007/s10151-014-1142-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2014] [Accepted: 03/17/2014] [Indexed: 11/26/2022]
|
31
|
Cardone E, Apice G, Rega D, Montesarchio L, Scala D, Granata C, Vallone P, Fiore F, Mori S, Delrio P. Salvage vacuum therapy after failed reconstruction of abdominal wall for extensive resection in recurrent uterine sarcoma. Eur J Surg Oncol 2013. [DOI: 10.1016/j.ejso.2013.07.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
32
|
Rega D, Montesarchio L, Cardone E, Ulloa Severino B, Pace U, Scala D, Ruffolo F, Sassaroli C, Delrio P. Transanal minimally invasive surgery (TAMIS) for local excision of rectal tumors. Eur J Surg Oncol 2013. [DOI: 10.1016/j.ejso.2013.07.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
33
|
Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P, Romano C, Giordano P, Lastoria S, Caracò C, de Lutio di Castelguidone E, Palaia R, Daniele G, Aloj L, Romano G, Iaffaioli RV. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer 2013; 108:1566-70. [PMID: 23558891 PMCID: PMC3668480 DOI: 10.1038/bjc.2013.140] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Background: Preoperative treatment of resectable liver metastases from colorectal cancer (CRC) is a matter of debate. The aim of this study was to assess the feasibility and activity of bevacizumab plus FOLFIRI in this setting. Methods: Patients aged 18–75 years, PS 0–1, with resectable liver-confined metastases from CRC were eligible. They received bevacizumab 5 mg kg−1 followed by irinotecan 180 mg m−2, leucovorin 200 mg m−2, 5-fluorouracil 400 mg m−2 bolus and 5-fluorouracil 2400 mg m−2 46-h infusion, biweekly, for 7 cycles. Bevacizumab was stopped at cycle 6. A single-stage, single-arm phase 2 study design was applied with 1-year progression-free rate as the primary end point, and 39 patients required. Results: From October 2007 to December 2009, 39 patients were enrolled in a single institution. Objective response rate was 66.7% (95% exact CI: 49.8–80.9). Of these, 37 patients (94.9%) underwent surgery, with a R0 rate of 84.6%. Five patients had a pathological complete remission (14%). Out of 37 patients, 16 (43.2%) had at least one surgical complication (most frequently biloma). At 1 year of follow-up, 24 patients were alive and free from disease progression (61.6%, 95% CI: 44.6–76.6). Median PFS and OS were 14 (95% CI: 11–24) and 38 (95% CI: 28–NA) months, respectively. Conclusion: Preoperative treatment of patients with resectable liver metastases from CRC with bevacizumab plus FOLFIRI is feasible, but further studies are needed to define its clinical relevance.
Collapse
|
34
|
Cardone E, Rega D, Scala D, Tammaro P, Sassaroli C, Mori S, Montesarchio L, Pace U, Delrio P. Options for pelvic floor reconstruction after extralevator abdomin-operineal resection (APR): Myocutaneous flap or porcine dermal collagen implant. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.07.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
35
|
Rega D, Cardone E, Montesarchio L, Tammaro P, Pace U, Ruffolo F, De Franciscis S, Belli A, Bianco F, Delrio P. Transanal minimally invasive surgery with single-port laparoscopy for rectal tumors. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.07.028] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
36
|
Avallone A, Di Gennaro E, Aloj L, Delrio P, Pecori B, Tatangelo F, Petrillo A, Iaffaioli V, Lastoria S, Budillon A. Neoadjuvant Multidisciplinary Phase II Study (BRANCH) of an Early Bevacizumab Schedule Plus Chemo-Radiation Therapy in Rectal Cancer: Efficacy, Safety, and Biomarkers. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33177-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
Cardone E, Delrio P, Avallone A, Pecori B, Budillon A, De Gennaro E, Lastoria S, Tatangelo F, Marone P, Petrillo A, Romano C, Sassaroli C, Bianco F, Cremona F, Romano G. Circulating endothelial cells and FDG-PET as markers for early prediction of response to neoadjuvant chemoradiation and bevacizumab for locally advanced rectal cancer. Eur J Surg Oncol 2010. [DOI: 10.1016/j.ejso.2010.06.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
38
|
Avallone A, Delrio P, Gennaro ED, Pecori B, Caracò C, Tatangelo F, Sandomenico C, Petrillo A, Budillon A, Comella P. 6117 Circulating endothelial cells (CECs) and FDG-PET for early prediction of response in high-risk locally advanced rectal cancer (HR-LARC) patients (pts) treated with two different schedules of bevacizumab (BEV) in combination with preoperative chemo-radiotherapy (CT-RT). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71212-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
39
|
Avallone A, Delrio P, Di Gennaro E, Pecori B, Aloi L, Tatangelo F, Petrillo A, Budillon A, Caracò C, Sandomenico C, Comella P. Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e14546] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14546 Background: OXA, RTX, 5FU, and LFA during preop pelvic RT produced a high rate of complete (TRG1) or subtotal (TRG2) tumor regression in HR-LARC. BEV might enhance response to chemoradiotherapy (CH-RT), but scheduling of BEV could be critical. Therefore, we added BEV to CH-RT in two different schedules to evaluate their feasibility and activity. According to the Simon's two-stage design, assuming a hypothesis of a 50% TRG1 (α=0.05, β=0.20), at least 6/16 TRG1 should be obtained to continue pts accrual in every schedule. Methods: Inclusion criteria were: cT4, cN+, cT3(<5 cm from the anal verge and/or +ve CRM), resectable M1. Pts received 3 biweekly courses(c) of OXA (100 mg/m2)/TOM (2.5 mg/m2) on day 1, and 5FU (800 mg/m2)/LFA(250 mg/m2) on day 2 during pelvic RT (45 Gy). BEV (5 mg/kg) was given biweekly from day -14 for 4 c in schedule A, and from day -4 for 2 c in schedule B. Toxicity was graded with NCI-CTCv3. Changes of circulating endothelial cells (CECs)assessed by flow cytometry in 17 (7 A; 10 B) pts, and glucose metabolism evaluated by FDG-PET in 27 (15 A; 12 B) pts after 1st c of CT were used as surrogate markers of tumor response. The Mann-Whitney test assessed the differences in CECs and FDG-PET related to schedules. TME was planned 8 wks after CH- RT. Results: Until now, 28 pts (16 A; 12 B) were treated: M/F=19/9; median age 57 (range, 43–74) yrs. All but one pt (A) completed the planned CH-RT. Grade 3/4 neutropenia was the most common toxicity with schedule A (7 pts, 44%), while it never occurred with schedule B. No treatment-related or postop death occurred. CECs were more decreased by schedule B than by schedule A (median, -78% vs -29%, p< 0.05). Glucose metabolism was also more reduced by schedule B (median, -78% vs -50%, p < 0.05). All but one pt (refusal) of schedule A, and 7 pts of schedule B proceeded to TME. With schedule A, 2 pts obtained a TRG1, 8 pts a TRG2, 3 pts a TRG3 and 2 pts a TRG4. With schedule B, 4 pts obtained a TRG1 and 3 pts a TRG2. Conclusions: These data suggest the relevance of BEV scheduling during preop CT-RT to optimize safety and efficacy of the combination treatment. Updated results on the whole study population will be presented. No significant financial relationships to disclose.
Collapse
|
40
|
Fattopace A, Canonico S, Guida A, Scala D, Ruffolo F, Cremona F, Pecori B, Guida C, Avallone A, Di Marzo M, Tatangelo F, Petrillo A, Marone P, Delrio P. Preoperative radiotherapy "short course" in rectal cancer in elder patient: low impact on tumor regression. BMC Geriatr 2009. [PMCID: PMC4290845 DOI: 10.1186/1471-2318-9-s1-a25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
41
|
Avallone A, Delrio P, Guida C, Tatangelo F, Petrillo A, Sandomenico C, Costanzo R, Parisi V, Comella G, Comella P. 3027 POSTER High rate of TRG1–2, and prolonged RFS with OXA/TOM and FU/LFA during preoperative pelvic RT in patients with poor prognosis locally-advanced rectal cancer (LARC). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70955-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
42
|
Avallone A, Delrio P, Guida C, Tatangelo F, Petrillo A, Lastoria S, Parisi V, Comella G, Budillon A, Comella P. High rate of TRG1–2 and prolonged RFS with OXA/TOM and FU/LFA during preoperative pelvic RT in patients with poor prognosis locally advanced rectal cancer (LARC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14500] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14500 Background: We have previously reported that 3 cycles of Oxaliplatin (OXA), Raltitrexed (TOM) and 5-Fluorouracile (FU) + levo-folinic acid (LFA) during pelvic RT had an acceptable toxicity and produced a complete (TRG1, 42%) or subtotal (TRG2, 29%) pathologic tumor regression in 71% of 31 pts with poor prognosis LARC (Avallone et al, Br J Cancer 2006). Here we report an expanded experience on such treatment. Methods: We enrolled 62 eligible pts (M, 33; F, 29), with median age of 58 (27–79) yrs, and adenocarcinoma of the extraperitoneal rectum, with at least one of the following characteristics: cT4 (N pts), cN+ (N), cT3N0 with tumor location = 5 cm from the anal verge and/or CRM +ve (assessed by MRI) (N). Pts received 3 biweekly courses of OXA 100 mg/sqm + TOM 2.5 mg/sqm on day 1, and LFA 250 mg/sqm + FU 900 mg/sqm (31 pts) or 800 mg/sqm (31 pts) on day 2, and concomitant pelvic RT (1.8 Gy/day, total dose 45 Gy). TME was planned 8 weeks after the end of treatment. Pathologic response was evaluated by tumor regression grading (TRG) according to Mandard’s modified classification. Pts with cT4, pN+ and pCRM +ve received also 4 months of weekly FU/FA. Results: All pts received full dose of RT, and 98% of the planned CT cycles. Neutropenia was the most common grade = 3 toxicity (40%), while grade 3 diarrhea was seen in 19% of pts with FU 900 mg/sqm, and in only 6% of pts with FU 800 mg/sqm. All but 2 pts had a TME with R0 resection, and no treatment-related or perioperative death occurred. Median number of sampled lymph nodes was 36 (range, 10–80). 28 (45%) pts obtained a TRG1, and 17 (27%) pts a TRG2. Activity of the treatment was similar in all risk groups, regardless of FU dosage. 1 pt suffered a local recurrence (after 9 months), and 3 pts had distant metastases (after 22, 33, and 47 months). After a median follow-up of 34 (range 6–54) months, all pts are alive, and the estimated 34-month RFS was 95%. All pts achieving a TRG1, and all but one with TRG2 (pCRM +ve), were recurrence-free. Conclusions: These data confirm the feasibility and activity of the whole treatment. A slight reduction of FU dosage appeared to improve the safety of this combination. Currently, we are now evaluating the addition of bevacizumab 5 mg/kg every 2 weeks before and during this concurrent treatment. No significant financial relationships to disclose.
Collapse
|
43
|
Papa ML, Capasso F, Pudore L, Torre S, Mango S, Russo V, Delrio P, Palaia R, Ruffolo F, d'Eufemia MD, De Lucia D, Napolitano M, Di Micco P, Parisi V. Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer. Exp Oncol 2007; 29:111-5. [PMID: 17704742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
BACKGROUND Quantification of the magnitude of thrombotic risk associated with malignancy and with anti-cancer therapy is indispensable to use anticoagulant drugs which selectively interfere with haemostatic mechanisms protecting patients from venous thromboembolism (VTE) and probably from tumor progression. However, none of activation coagulation markers has any predictive value for the occurrence of the thrombotic events in one individual patient. Current clotting methods can't reveal the overall dynamic clot formation; in contrast thromboelastographic methods specifically assess overall coagulation kinetics and its strength in whole blood. AIM Objective of study was to evaluate if the activation of coagulation as eventually revealed by ROTEM thromboelastometry could assess an hypercoagulable state in surgical neoplastic patients. PATIENTS AND METHODS Fifty consecutive patients with carcinoma of the digestive tract in preoperative period (23 M, 27 F aging 61.5 (45-79 years) and 147 healthy subjects (71 M, 76 F) were studied. A recent thromboelastometric method based on thrombelastography after Hartert was employed. Measurements were performed on ROTEM Coagulation Analyzer. The continuous coagulation data from 50 min course were transformed into dynamic velocity profiles of WB clot formation. RESULTS Standard parameters (CT, CFT, MCF) of cancer patients were similar to controls. CT (in cancer patients): females 50 s (38.3-58.7), males 50 s (42-71.2) vs 51 s (42-59), p = 0.1210 / 53 s (42-74.8), p = 0.1975 (in controls). CFT (in cancer patients): females 72 s (32- 92.4), males 80 s (50.2- 128.7) vs 78 s (62-100), p = 0.0128 / 80 s (59-124.4), p = 0.9384 (in controls). MCF (in cancer patients): females 70 mm (59.9-82.5), males 63 mm (56-73.7) vs 69 mm (59-95.8), p = 0.9911 / 69 mm (53.6-90), p = 0.0135 (in controls). Females showed a higher MaxVel when compared to males. The MaxVel was increased in cancer patients: females 19 mm /100 s (14.3-49.5) males 18 mm / 100 s (11-27) vs 15 mm 100 s (11.8-22), p < 0.001 / 13 mm / 100 s (10-21.8), p < 0.001 in controls. The t-MaxVel was shortened in cancer patients: females 65s (48.6-112.8), males 81s (50.1-135.9) vs 115s (56.8-166), p < 0.001 / 115 s (59.8-180.8), p = 0.0002 in controls. The AUC was increased in cancer patients: females 6451 mm 100(5511-8148), males 5984 mm 100 (5119-6899) vs 5778 mm 100 (4998-6655), p < 0.001 / 5662 mm 100 (4704-6385), p = 0.0105. CONCLUSION Unlike other assays measuring variations in a single component during coagulation, the thrombelastographic method records a profile of real-time continuous WB clot formation, and may provide extensive informations on haemostasis in neoplastic patients before surgery.
Collapse
|
44
|
Avallone A, Delrio P, Guida C, Tatangelo F, Petrillo A, Marone P, Cascini LG, Morrica B, Lastoria S, Parisi V, Budillon A, Comella P. Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study. Br J Cancer 2006; 94:1809-15. [PMID: 16736001 PMCID: PMC2361331 DOI: 10.1038/sj.bjc.6603195] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Oxaliplatin (OXA), raltitrexed (RTX), 5-fluorouracil (FU) and folinic acid (FA) have shown activity in metastatic colorectal cancer, radioenhancing effect and synergism when combined. We evaluated a chemotherapy (CT) combination of OXA, RTX and FU/FA during preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC) patients. Fifty-one patients with LARC at high risk of recurrence (T4, N+ or T3N0 ⩽5 cm from anal verge and/or circumferential resection margin ⩽5 mm) received three biweekly courses of CT during pelvic RT (45 Gy). Surgery was planned 8 weeks after CT-RT. Recommended doses (RDs) determined during phase I were utilised in the subsequent phase II trial, where the rate of tumour regression grade (TRG) 1 or 2 was the main end point. No toxic deaths occurred, and severe toxicity was easily managed. In phase II, RDs delivered in 31 patients were OXA 100 mg m−2 and RTX 2.5 mg m−2 on day 1, and FU 900 mg m−2 and LFA 250 mg m−2 on day 2. Main severe toxicities by patients were grade 4 neutropenia (23%) and grade 3 diarrhoea (19%). In 71% (95% confidence limits, 52–86%) of patients, TRG1 (13) or TRG2 (9) was obtained. All patients are alive and recurrence-free after a median follow-up of 29 months. Combination of OXA, RTX and FU/FA with pelvic RT has an acceptable toxicity and a high clinical activity in LARC and should be studied further in patients at high risk of recurrence.
Collapse
|
45
|
Avallone A, Lastoria D, Delrio P, Guida C, Tatangelo F, Marone P, Petrillo A, Budillon A, Cascini G, Comella P. High pathological response rate with neoadjuvant oxaliplatin (OXA), raltitrexed (TOM), 5-fluorouracil (FU) and levo-folinic acid (LFA) + RT in poor-risk locally advanced rectal cancer (LARC): Results of a phase II study with dynamic evaluation by FDG-PET scan. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Delrio P, Fazioli F, Di Marzo M, Avallone A, Elmo M, Pecori B, Ravo V, Idà DN, Bianchi P, Cremona F, De Rosa V, Parisi V. Combined multistep approach in a locally advanced rectal cancer with sacral invasion: case report. I SUPPLEMENTI DI TUMORI : OFFICIAL JOURNAL OF SOCIETA ITALIANA DI CANCEROLOGIA ... [ET AL.] 2005; 4:S7. [PMID: 16437870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Composite pelvic resection with sacrectomy may provide good local control in case of locally advanced rectal cancer infiltrating the sacral bone. A combined multidisciplinary approach including chemotherapy and radiotherapy is here presented for a case of rectal tumor invading the sacrum.
Collapse
|
47
|
Palaia R, Delrio P, Albino V, Scala D, Cremona F, Pignata S, Parisi V. [Evolution of the treatment of locoregional recurrences of gastric carcinoma]. I SUPPLEMENTI DI TUMORI : OFFICIAL JOURNAL OF SOCIETA ITALIANA DI CANCEROLOGIA ... [ET AL.] 2005; 4:S76. [PMID: 16437914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
|
48
|
Delrio P, Avallone A, Guida C, Lastoria S, Tatangelo F, Cascini GM, Marone P, Petrillo A, Budillon A, Di Marzo M, Palaia R, Albino V, De Rosa V, Parisi V. Multidisciplinary approach to locally advanced rectal cancer: results of a single institution trial. I SUPPLEMENTI DI TUMORI : OFFICIAL JOURNAL OF SOCIETA ITALIANA DI CANCEROLOGIA ... [ET AL.] 2005; 4:S8. [PMID: 16437871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Locally advanced rectal cancer carries out a dismail prognosis despite optimal surgery in terms of local and distant relapses. Neoadjuvant chemoradiation offers good results with tumor downstaging and downsizing and leads to more radical surgery with conservative intent. Selection of patients and an intensive chemotherapy may improve long term results. Our experience with a combined polichemotherapy and radiotherapy for low advanced rectal cancer is presented.
Collapse
|
49
|
Guida C, Delrio P, Avallone A, Ravo V, Elmo M, Pecori B, Silvestro G, Di marzo M, Lastoria S, Cascini G, Tempesta A, Morrica B. High pathological response rates with a novel preoperative chemoradiaton regimen in locally advanced rectal cancer: Preliminary results and dynamic evaluation by PET. Int J Radiat Oncol Biol Phys 2004. [DOI: 10.1016/j.ijrobp.2004.07.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
50
|
Avallone A, Delrio P, Ravo E, Marone P, Lastoria S, Petrillo A, Tatangelo F, Budillon A, Carreca I, Comella P. Neoadjuvant oxaliplatin (OXA), raltitrexed (TOM), 5- fluorouracil (FU) and folinic acid (FA) + radiotherapy followed by optimal surgery in locally advanced rectal cancer (LARC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|